by Daniel J Drucker Nature Reviews Drug Discovery
This review article discusses GLP-1-based therapies, highlighting their effectiveness for managing type 2 diabetes and obesity, including well-known drugs like semaglutide and tirzepatide. The text details the evolution of these medicines, from early shorter-acting versions to current long-acting injectables and promising oral formulations and multi-agonists. The review also covers the pharmacokinetics, efficacy, and safety profiles of approved and emerging therapies, emphasizing their benefits in reducing cardiovascular and renal complications. Furthermore, it explores the potential expansion of GLP-1-based drugs to treat a wide range of conditions, including sleep apnea, metabolic liver disease, and various neuropsychiatric disorders, underscoring the ongoing research and development in this field.
Audio Overview (Google NotebookLM)
(21 minutes 14 seconds)
